PMV PHARMACEUTICALS, INC. (PMVP) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
10/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LosePMVP / S&P 8.06% / 15.20% |
LosePMVP / S&P PMVP unavailable / 15.00% |
LosePMVP / S&P -9.55% / 50.40% |
| 2026-Q11/3 |
WinPMVP / S&P -0.80% / -4.33% |
LosePMVP / S&P PMVP unavailable / 11.30% |
LosePMVP / S&P 26.27% / 27.70% |
| 2025-Q41/3 |
LosePMVP / S&P -10.71% / 2.65% |
LosePMVP / S&P PMVP unavailable / 9.00% |
WinPMVP / S&P 30.70% / 13.40% |
| 2025-Q32/3 |
WinPMVP / S&P 32.08% / 8.12% |
LosePMVP / S&P PMVP unavailable / 4.61% |
WinPMVP / S&P 60.00% / 13.45% |
| 2025-Q21/3 |
LosePMVP / S&P -2.75% / 10.94% |
LosePMVP / S&P PMVP unavailable / 4.83% |
WinPMVP / S&P 61.86% / 10.63% |
| 2025-Q10/3 |
LosePMVP / S&P -27.81% / -4.27% |
LosePMVP / S&P PMVP unavailable / 4.98% |
LosePMVP / S&P -11.28% / 10.57% |
| 2024-Q40/3 |
LosePMVP / S&P 1.34% / 2.41% |
LosePMVP / S&P PMVP unavailable / 5.25% |
LosePMVP / S&P -21.38% / 6.15% |
| 2024-Q30/3 |
LosePMVP / S&P -8.02% / 5.89% |
LosePMVP / S&P PMVP unavailable / 5.89% |
LosePMVP / S&P -36.31% / 6.11% |
| 2024-Q20/3 |
LosePMVP / S&P -4.71% / 4.28% |
LosePMVP / S&P PMVP unavailable / 5.38% |
LosePMVP / S&P -40.49% / 5.12% |
| 2024-Q10/3 |
LosePMVP / S&P -45.16% / 10.56% |
LosePMVP / S&P PMVP unavailable / 5.71% |
LosePMVP / S&P -18.40% / 5.59% |
| 2023-Q40/3 |
LosePMVP / S&P -49.51% / 11.69% |
LosePMVP / S&P PMVP unavailable / 6.81% |
LosePMVP / S&P -10.49% / 7.78% |
| 2023-Q32/3 |
WinPMVP / S&P -1.92% / -3.27% |
LosePMVP / S&P PMVP unavailable / 7.52% |
WinPMVP / S&P -1.26% / -5.03% |
| 2023-Q22/3 |
WinPMVP / S&P 31.24% / 8.74% |
LosePMVP / S&P PMVP unavailable / 9.50% |
WinPMVP / S&P 7.24% / -8.57% |
| 2023-Q10/3 |
LosePMVP / S&P -45.17% / 7.50% |
LosePMVP / S&P PMVP unavailable / 10.77% |
LosePMVP / S&P PMVP unavailable / -15.69% |
| 2022-Q40/3 |
LosePMVP / S&P -26.89% / 7.56% |
LosePMVP / S&P PMVP unavailable / 11.88% |
LosePMVP / S&P PMVP unavailable / -17.99% |
| 2022-Q30/3 |
LosePMVP / S&P -16.49% / -4.88% |
LosePMVP / S&P PMVP unavailable / 13.47% |
LosePMVP / S&P PMVP unavailable / -1.41% |
| 2022-Q20/3 |
LosePMVP / S&P -31.56% / -16.10% |
LosePMVP / S&P PMVP unavailable / 13.71% |
LosePMVP / S&P PMVP unavailable / 11.04% |
| 2022-Q10/3 |
LosePMVP / S&P -9.87% / -4.60% |
LosePMVP / S&P PMVP unavailable / 15.97% |
LosePMVP / S&P PMVP unavailable / 42.23% |
| 2021-Q40/3 |
LosePMVP / S&P -22.48% / 11.03% |
LosePMVP / S&P PMVP unavailable / 15.00% |
LosePMVP / S&P PMVP unavailable / 96.40% |
| 2021-Q30/3 |
LosePMVP / S&P -12.76% / 0.58% |
LosePMVP / S&P PMVP unavailable / 10.77% |
LosePMVP / S&P PMVP unavailable / 69.42% |
| 2021-Q20/3 |
LosePMVP / S&P 3.86% / 8.55% |
LosePMVP / S&P PMVP unavailable / 6.58% |
LosePMVP / S&P PMVP unavailable / 51.81% |
| 2021-Q10/3 |
LosePMVP / S&P -46.53% / 6.17% |
LosePMVP / S&P PMVP unavailable / -1.06% |
LosePMVP / S&P PMVP unavailable / 7.39% |
| 2020-Q41/3 |
WinPMVP / S&P 73.27% / 12.15% |
LosePMVP / S&P PMVP unavailable / -3.72% |
LosePMVP / S&P PMVP unavailable / -33.42% |
| 2020-Q30/3 |
LosePMVP / S&P PMVP unavailable / 8.93% |
LosePMVP / S&P PMVP unavailable / -2.04% |
LosePMVP / S&P PMVP unavailable / -27.10% |
| 2020-Q20/3 |
LosePMVP / S&P PMVP unavailable / 20.54% |
LosePMVP / S&P PMVP unavailable / -0.46% |
LosePMVP / S&P PMVP unavailable / -27.11% |
| 2020-Q10/3 |
LosePMVP / S&P PMVP unavailable / -19.60% |
LosePMVP / S&P PMVP unavailable / 3.47% |
LosePMVP / S&P PMVP unavailable / -14.75% |
| 2019-Q40/3 |
LosePMVP / S&P PMVP unavailable / 9.07% |
LosePMVP / S&P PMVP unavailable / 5.36% |
LosePMVP / S&P PMVP unavailable / 2.99% |
| 2019-Q30/3 |
LosePMVP / S&P PMVP unavailable / 1.70% |
LosePMVP / S&P PMVP unavailable / 5.02% |
LosePMVP / S&P PMVP unavailable / 0.21% |
| 2019-Q20/3 |
LosePMVP / S&P PMVP unavailable / 4.30% |
LosePMVP / S&P PMVP unavailable / 6.64% |
LosePMVP / S&P PMVP unavailable / 8.65% |
| 2019-Q10/3 |
LosePMVP / S&P PMVP unavailable / 13.65% |
LosePMVP / S&P PMVP unavailable / 8.12% |
LosePMVP / S&P PMVP unavailable / 14.29% |
| 2018-Q40/3 |
LosePMVP / S&P PMVP unavailable / -13.52% |
LosePMVP / S&P PMVP unavailable / 9.05% |
LosePMVP / S&P PMVP unavailable / 18.23% |
| 2018-Q30/3 |
LosePMVP / S&P PMVP unavailable / 7.71% |
LosePMVP / S&P PMVP unavailable / 10.21% |
LosePMVP / S&P PMVP unavailable / 19.06% |
| 2018-Q20/3 |
LosePMVP / S&P PMVP unavailable / 3.43% |
LosePMVP / S&P PMVP unavailable / 9.03% |
LosePMVP / S&P PMVP unavailable / 14.46% |
| 2018-Q10/3 |
LosePMVP / S&P PMVP unavailable / -0.76% |
LosePMVP / S&P PMVP unavailable / 7.68% |
LosePMVP / S&P PMVP unavailable / 12.46% |
| 2017-Q40/3 |
LosePMVP / S&P PMVP unavailable / 6.64% |
LosePMVP / S&P PMVP unavailable / 7.03% |
LosePMVP / S&P PMVP unavailable / 13.82% |
| 2017-Q30/3 |
LosePMVP / S&P PMVP unavailable / 4.48% |
LosePMVP / S&P PMVP unavailable / 5.68% |
LosePMVP / S&P PMVP unavailable / 17.57% |
| 2017-Q20/3 |
LosePMVP / S&P PMVP unavailable / 3.09% |
LosePMVP / S&P PMVP unavailable / 4.83% |
LosePMVP / S&P PMVP unavailable / 17.74% |
| 2017-Q10/3 |
LosePMVP / S&P PMVP unavailable / 6.07% |
LosePMVP / S&P PMVP unavailable / 3.67% |
LosePMVP / S&P PMVP unavailable / 13.32% |
| 2016-Q40/3 |
LosePMVP / S&P PMVP unavailable / 3.82% |
LosePMVP / S&P PMVP unavailable / 2.09% |
LosePMVP / S&P PMVP unavailable / 7.05% |
| 2016-Q30/3 |
LosePMVP / S&P PMVP unavailable / 3.85% |
LosePMVP / S&P PMVP unavailable / 0.20% |
LosePMVP / S&P PMVP unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | PMVP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -11.43% | 20.78% |
| Annualized return | -11.43% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | PMVP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -95.89% | 83.14% |
| Annualized return | -47.19% | 12.86% |
10Y · 2020-09-25 to 2026-08-27
| Metric | PMVP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -96.69% | 319.30% |
| Annualized return | -28.89% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |